Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIA, open-label study to evaluate the immunogenicity and safety of sequential use of GSK's investigational vaccine GSK3277511A when administered to healthy smokers and ex-smokers aged 50 to 80 years following receipt of Shingrix vaccine

Next Previous
Trial Profile

A Phase IIA, open-label study to evaluate the immunogenicity and safety of sequential use of GSK's investigational vaccine GSK3277511A when administered to healthy smokers and ex-smokers aged 50 to 80 years following receipt of Shingrix vaccine

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 3277511 (Primary) ; AS01E; GSK 137173A
  • Indications Chronic obstructive pulmonary disease; Haemophilus infections; Moraxella infections
  • Focus Pharmacodynamics
  • Acronyms NTHI MCAT-009
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK

Most Recent Events

  • 02 Sep 2021 This trial has been completed in France (Global end date: 13 Aug 2021).
  • 29 Aug 2021 This trial has been completed in Finland (Global end date: 13 Aug 2021).
  • 24 Aug 2021 Number of treatment arms were increased from 4 to 5 by the addition of an Experimental: Shingrix-Only Group. It consisted of subjects who received at least 1, maximum 2 doses of GSK Biologicals Shingrix vaccine at Day 1 and Day 61, but didn't receive any dose of NTHI Mcat investigational vaccine. Only safety data were collected for these subjects.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top